Results 111 to 120 of about 4,101 (234)

Glofitamab in relapsed/refractory mantle cell lymphoma: Results from a phase I/II study [PDF]

open access: yes
PURPOSE: Patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) have a poor prognosis. The phase I/II NP30179 study (ClinicalTrials.gov identifier: NCT03075696) evaluated glofitamab monotherapy in patients with R/R B-cell lymphomas, with ...
Bartlett, Nancy L   +2 more
core   +2 more sources

Efficacy and Effectiveness Outcomes of Treatments for Double‐Exposed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Patients: A Systematic Literature Review

open access: yesCancer Medicine
Background Bruton's tyrosine kinase inhibitors (BTKi) and the B‐cell lymphoma 2 (BCL2) inhibitor venetoclax have significantly improved outcomes and achieved durable remission in patients with chronic lymphocytic leukemia (CLL).
Mohammed Zuber   +5 more
doaj   +1 more source

Exploring the role of IRF4 in the sensitivity of mantle cell lymphoma cells to Bruton\u27s Tyrosine Kinase inhibitors [PDF]

open access: yes
Introduction and aim: Mantle cell lymphoma (MCL) is an aggressive subtype of B-cell lymphoma. Therapy using Bruton’s tyrosine kinase (BTK) inhibitors has improved clinical outcomes but primary and secondary resistance to BTK inhibitor (BTKi) therapy ...
Portnojs, Artjoms
core   +1 more source

DP055 | DISTINCT RELAPSE PATTERNS IN CHRONIC LYMPHOCYTIC LEUKEMIA AFTER THERAPY WITH BTK OR BCL2 INHIBITORS

open access: yesHaematologica
Introduction Bruton tyrosine kinase inhibitors (BTKi) and venetoclax exert their effect on two different populations of chronic lymphocytic leukemia (CLL) cells: while BTKi act on the dividing subpopulation of CLL cells, which is killed after ...
F. Angotzi   +9 more
doaj  

Bruton tyrosine kinase inhibitor-related atrial fibrillation and its implications in the treatment of B-cell lymphoma

open access: yesFrontiers in Cardiovascular Medicine
Adverse events of atrial fibrillation (AF) have been commonly reported in lymphoma patients in treating Bruton's tyrosine kinase inhibitors (BTKi). The incidence rate of AF can vary depending on the specific types of BTKi and the patient population ...
Jun Du   +4 more
doaj   +1 more source

Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy [PDF]

open access: yes, 2018
Coats, Josh   +11 more
core   +3 more sources

Case report: Bruton tyrosine kinase inhibitor as therapy for chronic lymphocytic leukemia infiltrating a kidney allograft. [PDF]

open access: yes
The burden of chronic lymphocytic leukemia (CLL) in the prognosis of solid organ transplant (SOT) recipients seems non-negligible. Whether transplanting a patient with previous CLL is safe or what is the optimal monitoring and treatment management after ...
Dewarrat, N.   +4 more
core   +1 more source

The therapeutic perspective of relapsed/refractory Waldenström Macroglobulinemia: what comes next?

open access: yesFrontiers in Hematology
Waldenström Macroglobulinemia (WM) is a rare, indolent B-cell lymphoma that primarily affects elderly individuals. Although frontline chemoimmunotherapy and Bruton’s tyrosine kinase inhibitors (BTKi) can provide durable responses, most patients ...
Nicolò Danesin   +13 more
doaj   +1 more source

Labor Income Indices Designed for Use in Contracts Promoting Income Risk Management [PDF]

open access: yes
Labor income indices are created for groupings of individuals, using data from the Panel Study of Income Dynamics. People are grouped by a clustering algorithm based on an estimated transition matrix between jobs, by education level, and by skill ...
Robert J. Shiller, Ryan Schneider
core  

Home - About - Disclaimer - Privacy